|
|
|
Volumn 161, Issue 6, 1998, Pages 2672-2675
|
|
Cutting edge: Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor
a
a
a
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHEMOKINE;
CHEMOKINE RECEPTOR;
MACROPHAGE DERIVED CHEMOKINE;
UNCLASSIFIED DRUG;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
BETA CHEMOKINE;
CC CHEMOKINE RECEPTOR 4;
CCL22 CHEMOKINE;
IMMUNOLOGICAL ADJUVANT;
PEPTIDE FRAGMENT;
RECOMBINANT PROTEIN;
AMINO TERMINAL SEQUENCE;
ANTIGEN RECOGNITION;
ANTIVIRAL ACTIVITY;
ARTICLE;
CHEMOTAXIS;
MONOCYTE;
PRIORITY JOURNAL;
PROTEIN PROCESSING;
T LYMPHOCYTE;
ANIMAL;
CELL CULTURE;
DRUG EFFECT;
GENETICS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
IMMUNOLOGY;
LYMPHOCYTE;
METABOLISM;
MOUSE;
NEUTROPHIL CHEMOTAXIS;
PHYSIOLOGY;
SIGNAL TRANSDUCTION;
ADJUVANTS, IMMUNOLOGIC;
ANIMALS;
ANTI-HIV AGENTS;
CHEMOKINES, CC;
CHEMOTAXIS, LEUKOCYTE;
HIV-1;
HUMANS;
LYMPHOCYTES;
MICE;
MONOCYTES;
PEPTIDE FRAGMENTS;
RECEPTORS, CHEMOKINE;
RECOMBINANT PROTEINS;
SIGNAL TRANSDUCTION;
TUMOR CELLS, CULTURED;
|
|
EID: 0032530062
PISSN: 00221767
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (91)
|
|
References (25)
|
